Floatz logo

Infliximab

Clinical Stage 0 Cutaneous Melanoma AJCC v8

Therakos LLCmonoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

151 Active assets in the Clinical Stage 0 Cutaneous Melanoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB

View all 50 →

Same molecule, other indications

Infliximab is also rated in:

CachexiaDormant
BB
Indicative ·
64 / 100
View asset →
hepatosplenic T-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
colitisDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →